Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rowin

Showing results (191-200 of 209) with videos related to

Pageof 21
Sort By:
Circulation. Cardiovascular Interventions|July 13, 2019
Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical OutcomesCarey Kimmelstiel, David C Zisa, Johny S Kuttab, et al.
Circulation|January 1, 2013
Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of ageBarry J Maron, Ethan J Rowin, Susan A Casey, et al.
Journal of the American Heart Association|May 17, 2024
Relationship Between Genotype Status and Clinical Outcome in Hypertrophic CardiomyopathyJiri Bonaventura, Ethan J Rowin, Raymond H Chan, et al.
Heart Rhythm|January 27, 2024
Identification of high-risk imaging features in hypertrophic cardiomyopathy using electrocardiography: A deep-learning approachRichard T Carrick, Hisham Ahamed, Eric Sung, et al.
Circulation. Heart Failure|September 21, 2014
Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplantEthan J Rowin, Barry J Maron, Michael S Kiernan, et al.
Journal of the American College of Cardiology|April 28, 2022
Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic CardiomyopathyHao Cui, Hartzell V Schaff, Shuiyun Wang, et al.
Heart Rhythm|September 2, 2025
Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM TrialsEthan J Rowin, Martin S Maron, Iacopo Olivotto, et al.
Nature Communications|April 8, 2024
Author Correction: Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypesBradley A Maron, Rui-Sheng Wang, Sergei Shevtsov, et al.
Circulation. Arrhythmia and Electrophysiology|April 8, 2018
Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-DefibrillatorsBarry J Maron, Susan A Casey, Iacopo Olivotto, et al.
Nature Communications|February 9, 2021
Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypesBradley A Maron, Rui-Sheng Wang, Sergei Shevtsov, et al.
Pageof 21

Showing results (191-200 of 209) with videos related to

Sort By:
Pageof 21
Circulation. Cardiovascular Interventions|July 13, 2019
Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical OutcomesCarey Kimmelstiel, David C Zisa, Johny S Kuttab, et al.
Circulation|January 1, 2013
Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of ageBarry J Maron, Ethan J Rowin, Susan A Casey, et al.
Journal of the American Heart Association|May 17, 2024
Relationship Between Genotype Status and Clinical Outcome in Hypertrophic CardiomyopathyJiri Bonaventura, Ethan J Rowin, Raymond H Chan, et al.
Heart Rhythm|January 27, 2024
Identification of high-risk imaging features in hypertrophic cardiomyopathy using electrocardiography: A deep-learning approachRichard T Carrick, Hisham Ahamed, Eric Sung, et al.
Circulation. Heart Failure|September 21, 2014
Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplantEthan J Rowin, Barry J Maron, Michael S Kiernan, et al.
Journal of the American College of Cardiology|April 28, 2022
Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic CardiomyopathyHao Cui, Hartzell V Schaff, Shuiyun Wang, et al.
Heart Rhythm|September 2, 2025
Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM TrialsEthan J Rowin, Martin S Maron, Iacopo Olivotto, et al.
Nature Communications|April 8, 2024
Author Correction: Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypesBradley A Maron, Rui-Sheng Wang, Sergei Shevtsov, et al.
Circulation. Arrhythmia and Electrophysiology|April 8, 2018
Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-DefibrillatorsBarry J Maron, Susan A Casey, Iacopo Olivotto, et al.
Nature Communications|February 9, 2021
Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypesBradley A Maron, Rui-Sheng Wang, Sergei Shevtsov, et al.
Pageof 21